Virtus LifeSci Biotech Clinical Trials ETF
22 hedge funds and large institutions have $20.9M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.45% more ownership
Funds ownership: 40.35% → 42.8% (+2.5%)
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.17M | |
| 2 | +$408K | |
| 3 | +$141K | |
| 4 |
Morgan Stanley
New York
|
+$104K |
| 5 |
LPL Financial
San Diego,
California
|
+$39.5K |
Top Sellers
| 1 | -$635K | |
| 2 | -$293K | |
| 3 | -$34.6K | |
| 4 |
BRC
BHF RG Capital
Scottsdale,
Arizona
|
-$21.3K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$8.98K |